shopping cart
nothing in cart
 
browse by subject
new releases
best sellers
sale books
browse by author
browse by publisher
home
about us
upcoming events
Aug 26th - Integrating EMDR into Your Clinical Practice: Five-Day Intensive in Toronto [Leading Edge Seminars]
Sep 5th - Building Recovery Capital in Canada: Building on Our Strengths to Overcome Addiction - British Columbia [Last Door Recovery Society]
Sep 5th - COURSE ONE – Psychological Trauma: A Clinical Psychoanalytic Approach [tps&i - Toronto Psychoanalytic Society & Institute]
Sep 9th - 5-Session Clinical Extension Program: Autism Spectrum [Canadian Institute for Child & Adolescent Psychoanalytic Psychotherapy (CICAPP)]
Sep 11th - SCIENTIFIC MEETING – The Group at Work in Our Modern Internet Connected World: Teaching the Intervention of Infant-Parent Psychotherapy, using Zoom Internet Platform [tps&i - Toronto Psychoanalytic Society & Institute]
schools agencies and other institutional orders (click here)
Neuroprogression in Psychiatry
Kapczinski, Flavio, Pedro Viera Da Silva Magalhaes, and Michael Berk (Eds)
Oxford University Press / Softcover / 2019-04-01 / 0198787146
Psychiatry / Toronto Authors
price: $49.50
272 pages
In Stock (Ships within one business day)

Recent studies regarding the neuropathology of specific neurological disorders suggest that both neurodevelopmental and neurodegenerative processes may play a role. However, in contrast to the neurodegeneration seen in neurological disorders such as Parkinson's and Alzheimer's disease, the term "neuroprogression" has been used to describe the neurodevelopmental aspect of pathological brain re-wiring that takes place in the context of severe psychiatric disorders, such as schizophrenia or bipolar disorder. Within psychiatry, patients with severe psychopathology, such as those depressed patients who eventually commit suicide, have been shown to present with increased inflammatory markers in the brain. A similar increase in inflammatory markers is also found in patients with bipolar disorders and schizophrenia. Thus, oxidative stress, inflammation, and changes in growth factors are thought to be the pathways of neuroprogression.

Neuroprogression in Psychiatry provides a comprehensive summary of the current developments in the emerging field of neuroprogression. With contributions by leading researchers in the field, this book examines the role of neuroprogression across a wide range of specific psychiatric disorders, with chapters included on major depressive disorder, anxiety disorder, post-traumatic stress disorder, substance abuse, schizophrenia, and bipolar disorder.

Contents:

1. A short introductory note on neuroprogression and staging in psychiatry, Luis Guilherme Streb, Michael Berk, and Flavio Kapczinski
2. Allostasis and neuroprogression in major psychiatric disorders, Iria Grande, Flavio Kapczinski, Sebastian Caminoa, Gustavo Vazquez, and Eduard Vieta
3. Neuroprogression and accelerated aging in severe psychiatric disorders, Elisa Brietzke, Ana S. Yamagata, Pawan K. Maurya, and Lucas B. Rizzo
4. Mitochondrial function and inflammation pathways in the neuroprogression of mental disorders, Ana C. Andreazza, Rajas P. Kale, Angela Duong, Fabio Molina, and Susannah J.Tye
5. The role of immuno-inflammatory abnormalities in neuroprogression, Elisa Brietzke, Ana S. Yamagata, Raphael Cerqueira, Lucas B. Rizzo, Roger S. McIntyre, and Rodrigo B. Mansur
6. Depression and neuroprogression: Sirtuins and mitochondria as crucial hubs, George Anderson and Michael Maes
7. Neuroprogression in post-traumatic stress disorder, Ryan M. Cassidy, Ives Cavalcante Passos, and Marcia Kauer-Sant'Anna
8. Neuroprogression in anxiety disorders, Giampaolo Perna, Elisa Mingotto, Alessandra Alciati, and Daniela Caldirola
9. Functioning and illness progression in severe mental illness, Adriane R. Rosa and Flavia Lima
10. Neuropsychological functioning and neuroimaging in bipolar disorder: Evidence of neuroprogression, Emre Bora
11. Neuroprogression in children and adolescents with bipolar disorder, Francisco Romo-Nava, Jenni Farrow, Luis Rodrigo Patino, Fabiano Nery, Caleb M. Adler, and Melissa P. DelBello
12. Substance abuse and neuroprogression, Anne Orgler Sordi, Silvia Bassani Schuch-Goi, and Lisia von Diemen
13. Lifestyle and neuroprogression: Diet, sleep, and exercise, Adrian L. Lopresti and Peter D. Drummond
14. The pernicious procession of somatoprogression, Jonathan M. Gregory, Benjamin I. Goldstein, and Roger S. McIntyre

About the Editors:

Flavio Kapczinski, Professor, Department of Psychiatry and Behavioural Neurosciences, Director, Graduate Program in Neuroscience, McMaster University, Hamilton, ON, Canada,Michael Berk, Alfred Deakin Chair of Psychiatry, School of Medicine, Deakin University, Geelong, VIC, Australia; NHMRC Senior Principal Research Fellow, Department of Psychiatry, University of Melbourne, Parkville, VIC, Australia; Honorary Professorial Research Fellow, Florey Institute for Neuroscience and Mental Health and Orygen Youth Health, University of Melbourne, Parkville, VIC, Australia,Pedro Vieira da Silva Magalhaes, Adjunct Professor, Department of Psychiatry and Legal Medicine, Professor, Postgraduate Program in Psychiatry and Behavioral Sciences, Federal University of Rio Grande do Sul (UFRGS), Porto Alegre, RS, Brazil

Pedro Vieira da Silva Magalhaes is an Adjunct Professor in the Department of Psychiatry and Legal Medicine, and a Professor for the Postgraduate Program in Psychiatry and Behavioral Sciences, at the Federal University of Rio Grande do Sul (UFRGS), Porto Alegre, RS, Brazil.

Michael Berk is the Alfred Deakin Chair of Psychiatry in the School of Medicine, Deakin University, Geelong, VIC, Australia. He is also the NHMRC Senior Principal Research Fellow in the Department of Psychiatry at the University of Melbourne, Parkville, VIC, Australia, as well as an Honorary Professorial Research Fellow at the Florey Institute for Neuroscience and Mental Health and Orygen Youth Health, University of Melbourne, Parkville, VIC, Australia.

Contributors:

Caleb M. Adler, Department of Psychiatry and Behavioral Neuroscience, University of Cincinnati College of Medicine, Cincinnati, OH, USA

Alessandra Alciati, Department of Clinical Neurosciences, Villa San Benedetto Menni Hospital, Como, Italy

George Anderson, Clinical Research Center Scotland and London, London, UK

Ana C. Andreazza, Department of Pharmacology and Toxicology, University of Toronto, Toronto, ON, Canada; Institute of Medical Science, University of Toronto, Toronto, ON, Canada

Michael Berk, School of Medicine, Deakin University, Geelong, VIC, Australia; Department of Psychiatry, University of Melbourne, Parkville, VIC, Australia; Florey Institute for Neuroscience and Mental Health and Orygen Youth Health, University of Melbourne, Parkville, VIC, Australia

Emre Bora, Faculty of Medicine, Department of Psychiatry, Dokuz Eylul University, Izmir, Turkey; Department of Psychiatry, Royal Melbourne Hospital, University of Melbourne, Parkville, VIC, Australia

Elisa Brietzke, Mood Disorders Psychopharmacology Unit, Toronto Western Hospital, University Health Network, Toronto, ON, Canada; Department of Psychiatry, Federal University of Sao Paulo, Sao Paulo, RS, Brazil

Daniela Caldirola, Department of Clinical Neurosciences, Villa San Benedetto Menni Hospital, Como, Italy

Sebastian Camino, Dr. Braulio A. Moyano Neuropsychiatric Hospital, Buenos Aires, Argentina

Ryan M. Cassidy, Department of Psychiatry and Behavioral Sciences, The University of Texas Health Science Center, Houston, TX, USA

Raphael Cerqueira, Department of Psychiatry, Federal University of Sao Paulo, Sao Paulo, RS, Brazil

Melissa P. DelBello, Department of Psychiatry and Behavioral Neuroscience, University of Cincinnati College of Medicine, Cincinnati, OH, USA

Lisia von Diemen, Center for Drug and Alcohol Research, Hospital de Clinicas de Porto Alegre, Federal University of Rio Grande do Sul (UFRGS), Porto Alegre, RS, Brazil

Peter D. Drummond, School of Psychology and Exercise Science, Murdoch University, Perth, WA, Australia

Angela Duong, Department of Pharmacology and Toxicology, University of Toronto, Toronto, ON, Canada

Jenni Farrow, Department of Psychiatry and Behavioral Neurosciences, University of Cincinnati College of Medicine, Cincinnati, OH, USA

Iria Grande, Hospital Clinic, Institute of Neurosciences, University of Barcelona, IDIBAPS, CIBERSAM, Barcelona, Spain

Jonathan M. Gregory, Department of Psychiatry, Schulich School of Medicine and Dentistry, Western University, London, ON, Canada

Benjamin I. Goldstein, Department of Psychiatry, University of Toronto, Toronto, ON, Canada

Rajas P. Kale, Department of Psychiatry and Psychology, Mayo Clinic, Rochester, MN, USA; School of Engineering, Deakin University, Waurn Ponds, VIC, Australia

Flavio Kapczinski, Department of Psychiatry and Behavioural Neurosciences, Graduate Program in Neuroscience, McMaster University, Hamilton, ON, Canada

Marcia Kauer-Sant'Anna, Department of Psychiatry, Hospital de Clinicas de Porto Alegre, Federal University of Rio Grande do Sul (UFRGS), Porto Alegre, RS, Brazil; Postgraduate Program in Psychiatry, Federal University of Rio Grande do Sul (UFRGS), Porto Alegre, RS, Brazil; Bipolar Disorder Program and Laboratory of Molecular Psychiatry, Federal University of Rio Grande do Sul (UFRGS), Porto Alegre, RS, Brazil

Flavia Lima, Postgraduate Program in Psychiatry, Federal University of Rio Grande do Sul (UFRGS), Porto Alegre, RS, Brazil

Adrian L. Lopresti, School of Psychology and Exercise Science, Murdoch University, Perth, WA, Australia

Michael Maes, School of Medicine, Deakin University, Geelong, VIC, Australia; Department of Psychiatry, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand; Department of Psychiatry, Medical University of Plovdiv, Plovdiv, Bulgaria

Rodrigo B. Mansur, Mood Disorders Psychopharmacology Unit, Toronto Western Hospital, University Health Network, Toronto, ON, Canada; Department of Psychiatry, University of Toronto, Toronto, ON, Canada

Pawan K. Maurya, Department of Psychiatry, Federal University of Sao Paulo, Sao Paulo, RS, Brazil

Roger S. McIntyre, Mood Disorders Psychopharmacology Unit, Toronto Western Hospital, University Health Network, Toronto, ON, Canada; Department of Psychiatry, University of Toronto, Toronto, ON, Canada; Department of Pharmacology and Toxicology, University of Toronto, Toronto, ON, Canada; The Brain and Cognition Discovery Foundation, Toronto, ON, Canada

Elisa Mingotto, Department of Clinical Neurosciences, Villa San Benedetto Menni Hospital, Como, Italy

Fabio Molina, Department of Pharmacology and Toxicology, University of Toronto, Toronto, ON, Canada

Fabiano Nery, Department of Psychiatry and Behavioral Neuroscience, University of Cincinnati College of Medicine, Cincinnati, OH, USA

Anne Orgler Sordi, Center for Drug and Alcohol Research, Hospital de Clinicas de Porto Alegre, Federal University of Rio Grande do Sul (UFRGS), Porto Alegre, RS, Brazil

Ives Cavalcante Passos, Bipolar Disorder Program and Laboratory of Molecular Psychiatry, Federal University of Rio Grande do Sul (UFRGS), Porto Alegre, RS, Brazil; Department of Psychiatry, Federal University of Rio Grande do Sul (UFRGS), Porto Alegre, RS, Brazil

Luis Rodrigo Patino, Department of Psychiatry and Behavioral Neuroscience, University of Cincinnati College of Medicine, Cincinnati, OH, USA

Giampaolo Perna, Department of Clinical Neurosciences, Villa San Benedetto Menni Hospital, Como, Italy; Department of Psychiatry and Neuropsychology, University of Maastricht, Maastricht, The Netherlands; Department of Psychiatry and Behavioral Sciences, Leonard Miller School of Medicine, University of Miami, Miami, FL, USA

Lucas B. Rizzo, Department of Psychiatry, Federal University of Sao Paulo, Sao Paulo, RS, Brazil; Department of Psychiatry, University of Tuebingen, Tuebingen, Germany

Francisco Romo-Nava, Department of Psychiatry and Mental Health, Faculty of Medicine, National Autonomous University of Mexico (UNAM), Mexico City, DF, Mexico; Department of Psychiatry and Behavioral Neuroscience, University of Cincinnati College of Medicine, Cincinnati, OH, USA

Adriane R. Rosa, Laboratory of Molecular Psychiatry, Hospital de Clinicas de Porto Alegre, Federal University of Rio Grande do Sul (UFRGS), Porto Alegre, RS, Brazil; Department of Pharmacology and Postgraduate Program in Pharmacology, Federal University of Rio Grande do Sul (UFRGS), Porto Alegre, RS, Brazil

Silvia Bassani Schuch-Goi, Center for Drug and Alcohol Research, Hospital de Clinicas de Porto Alegre, Federal University of Rio Grande do Sul (UFRGS), Porto Alegre, RS, Brazil

Luis Guilherme Streb, Hospital Nossa Senhora da Conceicao, Porto Alegre, RS, Brazil

Susannah J. Tye, Department of Psychiatry and Psychology, Mayo Clinic, Rochester, MN, USA; Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, MN, USA; Department of Psychiatry, University of Minnesota, Minneapolis, MN, USA; School of Psychology, Deakin University, Burwood, VIC, Australia; Queensland Brain Institute, The University of Queensland, St Lucia, QLD, Australia

Gustavo Vazquez, International Consortium for Bipolar and Psychotic Disorder Research, McLean Hospital, Belmont, MA, USA; Department of Neuroscience, Palermo University, Buenos Aires, Argentina; Department of Psychiatry, Queens University, Kingston, ON, Canada

Eduard Vieta, Hospital Clinic, Institute of Neurosciences, University of Barcelona, IDIBAPS, CIBERSAM, Barcelona, Spain

Ana S. Yamagata, Department of Psychiatry, Federal University of Rio Grande do Sul (UFRGS), Sao Paulo, RS, Brazil

Caversham Booksellers
98 Harbord St, Toronto, ON M5S 1G6 Canada
(click for map and directions)
All prices in $cdn
Copyright 2019

Phone toll-free (800) 361-6120
Tel (416) 944-0962 | Fax (416) 944-0963
E-mail info@cavershambooksellers.com
Hours: 9-6 M-W / 9-7 Th-F / 10-6 Sat / 12-5 Sun EST

search
Click here to read previous issues.
authors
Berk, Michael
Kapczinski, Flavio
other lists
April 2019 New Arrivals
Canadian Authors
Oxford University Press
Psychiatry
Toronto Authors